Clinical Trial Update: KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

This document provides an update on KYSA-5, Kyverna Therapeutics' CD19 CAR T-cell trial for systemic sclerosis, indicating the study remains active but not curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• KYSA-5 (CD19-directed CAR T-cell therapy)

Snippet

Sponsor: Kyverna Therapeutics | Conditions: Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING